Standout Papers
Citation Impact
Citing Papers
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
2014
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
2010
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2014
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
2004
Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial
2006
Triple-Negative Breast Cancer: An Unmet Medical Need
2011
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
2018
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
2012
Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
2004
Triple-Negative Breast Cancer
2010 Standout
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 Standout
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
2015
Pancreatic cancer
2004 Standout
Changing Concepts of Hormone Receptor–Positive Advanced Breast Cancer Therapy
2012
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Breast cancer
2016 Standout
Aromatase Inhibitors in Breast Cancer
2003
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial
2015
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
2010
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer
2002
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials
2015
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Historical perspective on hormonal therapy of advanced breast cancer
2002
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
A Good Drug Made Better: The Fulvestrant Dose-Response Story
2014
Rolapitant: First Global Approval
2015
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
2016
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
2011
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
2003
Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
2003
Complexities of TGF-β Targeted Cancer Therapy
2012
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
2003
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
2008
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
2014
Clonal evolution in cancer
2012 StandoutNature
Ixabepilone for the treatment of breast cancer
2011
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
2018
Lessons learned from independent central review
2008
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
The PI3K Pathway in Human Disease
2017 Standout
Endocrine treatment options for advanced breast cancer – the role of fulvestrant
2004
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
2017
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Fluorine in medicinal chemistry
2007 Standout
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer
2007
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?
2008
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
2014 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
2008
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
2014
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
NCCN Task Force Report: Management of Neuropathy in Cancer
2009
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
2015
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
2012 Standout
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297
2002
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
2016
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Metastatic Prostate Cancer
2018
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling
2005 StandoutScience
Works of Luis Fein being referenced
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
2010
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)
2015
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer
2009
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer
2010
Exemestane Improves Survival in Metastatic Breast Cancer: Results of a Phase III Randomized Study
2000
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Phase II trial of gemcitabine (GEM), 5-Fluoruracil (5-FU) and leucovorin (LV) in advanced pancreatic cancer (PC)
1999
Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT
2008
Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial
2000
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
2007 Nobel
A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma
1999
3055 POSTER Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) progressing on or after prior irinotecan therapy: final results of the LABEL study
2007